We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICH to Revise 16-Year-Old Pediatric Drug Development Guideline
ICH to Revise 16-Year-Old Pediatric Drug Development Guideline
The International Council for Harmonization has identified the key scientific issues pediatric drug developers must address early on to improve the prospects for a drug’s approval later in the development process, in a draft that updates a 16-year-old efficacy guideline.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor